Hologic (NASDAQ:HOLX) Reaches New 12-Month Low – Time to Sell?

Hologic, Inc. (NASDAQ:HOLX)’s stock price reached a new 52-week low on Monday . The stock traded as low as $56.27 and last traded at $57.90, with a volume of 4235273 shares changing hands. The stock had previously closed at $57.16.

Analyst Ratings Changes

A number of equities analysts have issued reports on HOLX shares. Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Citigroup reduced their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Down 1.7 %

The stock’s fifty day moving average price is $62.04 and its 200-day moving average price is $71.25. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $12.98 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp increased its holdings in Hologic by 115.8% during the third quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider’s stock worth $1,658,000 after buying an additional 10,924 shares during the last quarter. Barclays PLC grew its position in shares of Hologic by 47.6% in the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after acquiring an additional 231,578 shares during the period. Sanctuary Advisors LLC increased its stake in shares of Hologic by 4.2% during the 3rd quarter. Sanctuary Advisors LLC now owns 16,613 shares of the medical equipment provider’s stock worth $1,312,000 after purchasing an additional 667 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Hologic in the 3rd quarter valued at about $93,000. Finally, Tidal Investments LLC lifted its stake in Hologic by 60.1% in the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock valued at $1,250,000 after purchasing an additional 5,764 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.